Universal Beteiligungs und Servicegesellschaft mbH Has $23.16 Million Stock Holdings in IQVIA Holdings Inc. (NYSE:IQV)

Universal Beteiligungs und Servicegesellschaft mbH boosted its holdings in IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 2.6% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 131,369 shares of the medical research company's stock after acquiring an additional 3,375 shares during the quarter. Universal Beteiligungs und Servicegesellschaft mbH owned 0.07% of IQVIA worth $23,160,000 at the end of the most recent quarter.

Several other large investors have also recently added to or reduced their stakes in the business. Continuum Advisory LLC increased its position in shares of IQVIA by 3.7% during the 4th quarter. Continuum Advisory LLC now owns 1,803 shares of the medical research company's stock valued at $354,000 after purchasing an additional 64 shares during the period. Ballentine Partners LLC increased its position in shares of IQVIA by 4.9% during the 1st quarter. Ballentine Partners LLC now owns 1,477 shares of the medical research company's stock valued at $260,000 after purchasing an additional 69 shares during the period. ST Germain D J Co. Inc. increased its position in shares of IQVIA by 66.1% during the 1st quarter. ST Germain D J Co. Inc. now owns 191 shares of the medical research company's stock valued at $34,000 after purchasing an additional 76 shares during the period. Zions Bancorporation N.A. increased its position in shares of IQVIA by 55.2% during the 4th quarter. Zions Bancorporation N.A. now owns 239 shares of the medical research company's stock valued at $47,000 after purchasing an additional 85 shares during the period. Finally, Quadrant Capital Group LLC increased its position in shares of IQVIA by 10.7% during the 4th quarter. Quadrant Capital Group LLC now owns 928 shares of the medical research company's stock valued at $182,000 after purchasing an additional 90 shares during the period. 89.62% of the stock is currently owned by institutional investors and hedge funds.

IQVIA Stock Down 0.8%

IQV traded down $1.65 during trading on Friday, reaching $199.17. 2,138,911 shares of the stock traded hands, compared to its average volume of 2,043,734. IQVIA Holdings Inc. has a fifty-two week low of $134.65 and a fifty-two week high of $252.88. The stock's 50-day simple moving average is $155.96 and its two-hundred day simple moving average is $170.53. The stock has a market cap of $33.86 billion, a price-to-earnings ratio of 28.82, a price-to-earnings-growth ratio of 2.29 and a beta of 1.30. The company has a debt-to-equity ratio of 2.45, a current ratio of 0.84 and a quick ratio of 0.82.

IQVIA (NYSE:IQV - Get Free Report) last announced its quarterly earnings results on Tuesday, July 22nd. The medical research company reported $2.81 earnings per share for the quarter, topping analysts' consensus estimates of $2.77 by $0.04. IQVIA had a return on equity of 30.05% and a net margin of 7.88%. The company had revenue of $4.02 billion during the quarter, compared to analysts' expectations of $3.96 billion. During the same quarter in the previous year, the firm earned $2.64 earnings per share. The business's quarterly revenue was up 5.3% compared to the same quarter last year. As a group, equities research analysts expect that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on the company. Mizuho lifted their price target on IQVIA from $190.00 to $225.00 and gave the company an "outperform" rating in a research report on Friday. HSBC cut IQVIA from a "buy" rating to a "hold" rating and lowered their price target for the company from $260.00 to $160.00 in a research report on Friday, April 25th. JPMorgan Chase & Co. decreased their target price on IQVIA from $232.00 to $177.00 and set an "overweight" rating on the stock in a report on Monday, May 19th. Cowen restated a "buy" rating on shares of IQVIA in a report on Wednesday. Finally, Barclays lifted their target price on IQVIA from $165.00 to $185.00 and gave the stock an "equal weight" rating in a report on Wednesday. Seven analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $228.62.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.